Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CTNM
Upturn stock ratingUpturn stock rating

Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

Upturn stock ratingUpturn stock rating
$3.97
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CTNM (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $23.71

1 Year Target Price $23.71

Analysts Price Target For last 52 week
$23.71Target price
Low$3.35
Current$3.97
high$21.92

Analysis of Past Performance

Type Stock
Historic Profit -20.55%
Avg. Invested days 21
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 106.33M USD
Price to earnings Ratio -
1Y Target Price 23.71
Price to earnings Ratio -
1Y Target Price 23.71
Volume (30-day avg) 5
Beta -
52 Weeks Range 3.35 - 21.92
Updated Date 06/30/2025
52 Weeks Range 3.35 - 21.92
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.49

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -22.95%
Return on Equity (TTM) -33.03%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -78117219
Price to Sales(TTM) 11.15
Enterprise Value -78117219
Price to Sales(TTM) 11.15
Enterprise Value to Revenue 8.25
Enterprise Value to EBITDA 20.76
Shares Outstanding 19142400
Shares Floating 13167066
Shares Outstanding 19142400
Shares Floating 13167066
Percent Insiders 1.82
Percent Institutions 79.99

Analyst Ratings

Rating 3
Target Price 23.71
Buy 2
Strong Buy 3
Buy 2
Strong Buy 3
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Contineum Therapeutics, Inc. Class A Common Stock

stock logo

Company Overview

overview logo History and Background

Contineum Therapeutics, Inc., formerly known as Vitae Pharmaceuticals, Inc., was founded in 2018. It focuses on developing novel therapies targeting specific biological pathways to treat unmet medical needs in neuroinflammation, neurodegeneration, and immunology. Initial focus was on treatments of Parkinson's and Multiple Sclerosis

business area logo Core Business Areas

  • Neuroinflammation: Focuses on developing therapies that address inflammation in the nervous system, potentially impacting conditions like multiple sclerosis.
  • Neurodegeneration: Develops treatments aimed at preventing or slowing the progression of neurodegenerative diseases like Parkinson's disease.
  • Immunology: Develops therapies to treat a variety of immune mediated diseases.

leadership logo Leadership and Structure

The leadership team includes executives with extensive experience in pharmaceutical research, development, and commercialization. Organizational structure typically includes departments for research and development, clinical trials, regulatory affairs, and business development. The CEO is Dewey Steadman.

Top Products and Market Share

overview logo Key Offerings

  • PAC-14028: A small molecule MRS1967 agonist designed to be highly selective for subtype 4 of the metabotropic glutamate receptor (M4), which is a G protein-coupled receptor. Currently in Phase 2 clinical trials for multiple sclerosis. Competitors include companies developing other MS therapies, such as Biogen (BIIB) and Novartis (NVS).
  • PAC-812: A selective inhibitor of the LPA1 receptor for Parkinson's Disease and Progressive Supranuclear Palsy. Competitors include companies developing Parkinson's and PSP therapies, such as Biogen (BIIB), Roche (RHHBY) and UCB.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. There's growing demand for innovative therapies targeting neurological disorders and immunological diseases.

Positioning

Contineum Therapeutics is positioned as a clinical-stage biotechnology company focused on novel therapies. Competitive advantages potentially include its targeted approach to modulating specific biological pathways.

Total Addressable Market (TAM)

The total addressable market for neuroinflammatory, neurodegenerative, and immunological diseases is substantial, estimated to be hundreds of billions of dollars annually. Contineum's positioning in specific disease areas allows it to capture a segment of this market.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic targets
  • Experienced management team
  • Strong intellectual property portfolio
  • Clinical-stage pipeline

Weaknesses

  • Dependence on clinical trial outcomes
  • High R&D expenditure
  • Limited commercial infrastructure
  • Competition from larger pharmaceutical companies

Opportunities

  • Successful clinical trial results
  • Strategic partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Accelerated regulatory pathways

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from existing therapies
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • Biogen (BIIB)
  • Novartis (NVS)
  • Roche (RHHBY)
  • UCB (UCBJF)

Competitive Landscape

Contineum Therapeutics faces competition from established pharmaceutical companies with greater resources and commercial infrastructure. Its competitive advantage lies in its novel therapeutic targets and selective approaches.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by R&D investment and advancement of clinical programs.

Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates would be required for specific projections.

Recent Initiatives: Recent initiatives include advancing PAC-14028 and PAC-812 through clinical trials, seeking partnerships, and optimizing its drug discovery platform.

Summary

Contineum Therapeutics is a clinical-stage biotech company with promising novel therapies in the neuroinflammation and neurodegeneration spaces. The company's success is heavily dependent on the outcome of its clinical trials. Securing partnerships with larger pharmaceutical companies could provide significant resources and validation. Risks include clinical trial failures and competition from established players. Overall, Contineum is a high-risk, high-reward investment.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports (where available)
  • ClinicalTrials.gov

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is approximate and may vary depending on the source.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Contineum Therapeutics, Inc. Class A Common Stock

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2024-04-05
President, CEO & Director Mr. Carmine N. Stengone MBA, MS
Sector Healthcare
Industry Biotechnology
Full time employees 41
Full time employees 41

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.